Another Tool for the Sexual Health Toolkit: US Health Care Provider Knowledge and Attitudes About Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections Among Men Who Have Sex With Men
- PMID: 39481014
- DOI: 10.1097/OLQ.0000000000002095
Another Tool for the Sexual Health Toolkit: US Health Care Provider Knowledge and Attitudes About Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infections Among Men Who Have Sex With Men
Abstract
Background: Doxycycline post-exposure prophylaxis (doxy-PEP) reduces chlamydia, gonorrhea, and syphilis infections among men who have sex with men (MSM) and transwomen (TW). Perspectives of health care providers (HCPs) regarding doxy-PEP can inform implementation efforts.
Methods: From August 2022 to January 2023, HCPs were recruited from 13 cities with high sexually transmitted infection (STI) rates for semi-structured, in-depth interviews about their awareness of and attitudes toward doxy-PEP for STI prevention. Health care providers were purposively sampled to include people with experience prescribing PrEP and provision of care to MSM. Interviews were conducted virtually via Zoom. Transcripts and debrief reports were analyzed using a directed content analysis approach to explore knowledge, attitudes, and beliefs about doxy-PEP.
Results: Among 30 HCPs, almost half (47%) were between 31-40 years of age, 53% identified as male, and 47% reported their sexual orientation as gay or queer. Half (53%) of participants practiced in the South, 43% had >100 MSM in their clinic panel, and 17% had previously prescribed doxy-PEP. We identified four overarching themes: 1) HCPs expressed positive attitudes toward doxy-PEP; 2) antimicrobial resistance concerns limit enthusiasm for some HCPs; 3) additional data about the long-term safety of doxy-PEP would improve their confidence; and 4) development of guidelines would facilitate the prescription of doxy-PEP, including eligibility, dosing instructions, and treatment management.
Conclusion: HCPs were motivated to prescribe doxy-PEP with almost 20% already having prescribed it. Guidelines and data about long-term safety, especially antimicrobial resistance, would facilitate introduction of doxy-PEP into clinical practice.
Copyright © 2024 American Sexually Transmitted Diseases Association. All rights reserved.
Conflict of interest statement
Conflict of Interest and Sources of Funding: None declared.
Similar articles
-
Doxycycline to prevent bacterial sexually transmitted infections in the USA: final results from the DoxyPEP multicentre, open-label, randomised controlled trial and open-label extension.Lancet Infect Dis. 2025 Aug;25(8):873-883. doi: 10.1016/S1473-3099(25)00085-4. Epub 2025 Mar 24. Lancet Infect Dis. 2025. PMID: 40147465 Clinical Trial.
-
Willingness to accept Doxycycline post-exposure prophylaxis for bacterial stis prevention among men who have sex with men in Southern China: a cross-sectional analysis.BMC Infect Dis. 2025 Jul 11;25(1):911. doi: 10.1186/s12879-025-11290-x. BMC Infect Dis. 2025. PMID: 40646493 Free PMC article.
-
Rapid Diffusion of Awareness and Uptake of Doxy-PEP among Men who Have Sex with Men in San Francisco.AIDS Behav. 2025 Jul;29(7):2043-2053. doi: 10.1007/s10461-025-04728-5. Epub 2025 Apr 28. AIDS Behav. 2025. PMID: 40289038
-
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Cochrane Database Syst Rev. 2008. PMID: 18646068
-
Strategies for partner notification for sexually transmitted infections, including HIV.Cochrane Database Syst Rev. 2013 Oct 3;2013(10):CD002843. doi: 10.1002/14651858.CD002843.pub2. Cochrane Database Syst Rev. 2013. PMID: 24092529 Free PMC article.
Cited by
-
Interest and disparities in awareness and uptake of doxycycline postexposure prophylaxis among US MSM with HIV.AIDS. 2025 Jul 15;39(9):1191-1196. doi: 10.1097/QAD.0000000000004192. Epub 2025 Mar 27. AIDS. 2025. PMID: 40162974
References
-
- Gandhi M, Spinelli MA, Mayer KH. Addressing the Sexually Transmitted Infection and HIV Syndemic. Jama . 2019; 32:1356–1358.
-
- Luetkemeyer A, Dombrowski J, Cohen S, et al. Doxycycline post-exposure prophylaxis for STI prevention among MSM and transgender women on HIV PrEP or living with HIV: high efficacy to reduce incident in a randomized trial. Montreal, Canada: Presented at: AIDS 2022, 2022. https://programme.aids2022.org/Abstract/Abstract/?abstractid=13231 .
-
- Bachmann LH. CDC Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial Sexually Transmitted Infection Prevention, United States, 2024. MMWR Recommendations and Reports . 2024; 73:1–8.
-
- Molina JM, Charreau I, Chidiac C, et al. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis . 2018; 18:308–317.
-
- Luetkemeyer AF, Donnell D, Dombrowski JC, et al. Postexposure Doxycycline to Prevent Bacterial Sexually Transmitted Infections. New England Journal of Medicine . 2023; 388:1296–1306.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous